Hong Kong stock anomaly | Hansen Pharmaceutical (03692.HK) rose over 3%. The HS-20093 phase III clinical study for the treatment of small cell lung cancer has reached its primary endpoint.

According to the Wise Finance and Economics APP, Hansoh Pharmaceutical (03692.HK) has risen by more than 3%, as of the time of writing, it rose by 3.38%, to 32.94 Hong Kong dollars, with a turnover of 127 million Hong Kong dollars.